Browse by category

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Dr Elizabeth McDonald, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing brea

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Innovent Biologics has announced that the outcomes of high-dose cohorts in a phase 1 clinical trial of mazdutide (IBI362) - a...

Beyond conventional metabolism, drugs based on GLP-1 can also reduce plaque formation in arteries and control inflammation in several...